The effect of administration of amodiaquine on some Parameters of neurobehaviour of wistar rats by Ekong, M.B et al.
51 
 
Nigerian Journal of Physiological Sciences 23 (1-2): 51 - 54 ©Physiological Society of Nigeria, 2008 
Available online/abstracted at http://www.bioline.org.br/np; www.ajol.info/journals.nips; www.cas.org 
 
THE EFFECT OF ADMINISTRATION OF AMODIAQUINE ON SOME 
PARAMETERS OF NEUROBEHAVIOUR OF WISTAR RATS 
 
 
M. B. EKONG, A. O. IGIRI, and O. E. MESEMBE 
 
Department of Anatomy, Faculty of Basic Medical Sciences, University of Calabar, Calabar, Nigeria 
Email: mbe_flashpoint@yahoo.com 
 
Summary: The effect of administration of Amodiaquine (AQ) on some parameters of neurobehaviour 
of Wistar rats was carried out.  Twenty adult Wistar rats weighing between 160-190g were divided 
equally into four groups.  Group 1 served as the control, while groups 2, 3 and 4 were the experimental 
groups.  The control group received distilled water.  Groups 2 and 3 were treated with 8.75mg/kg and 
17.50mg/kg respectively of AQ for three days, while group 4 was treated with 8.75mg/kg of AQ for six 
days.  Neurobehaviour test using the open field was carried out twelve hours after the last 
administrations. There were no significant differences between the control and the experimental groups 
in total locomotor activity (TLA), central square duration (CSD), stretch-attend (SA) and defecation.  
In the central square frequency (CSF), group 3 was significantly (P<0.05) higher than all the groups, 
while the control was the same as group 4, but higher than group 2, with the difference not being 
significant.  In conclusion, AQ increased TLA and exploration, while simultaneously reducing anxiety 
in Wistar rats and these were dose dependent. 
 




Amodiaquine (AQ) is a 4-aminoquinoline 
antimalarial drug with a similar mode of action 
to chloroquine. It is schizonticidal and 
possesses antipyretic and anti-inflammatory 
properties as well.  It is effective against the 
erythrocytic stages of all four species of 
Plasmodium falciparum (Olliaro and Mussano, 
2003). AQ like other 4-aminoquinolines 
accumulates in the lysosomes of the parasites 
and brings about loss of function, making the 
parasites unable to digest haemoglobin, which it 
depends upon for its energy. This drug binds to 
nucleoproteins of the parasites and inhibits its 
DNA and RNA polymerases (O’Neill et al, 
1998).  It generates free radicals in the form of 
AQ quinine immine and semi quinine immine 
which have been implicated in lipid 
peroxidation (Maggs et al, 1988).   
AQ has been known to cause several 
adverse reactions (Maggs et al, 1988).  Most of 
these reactions are not documented because of 
few scientific researches and the initial 
withdrawal of the drug.  Furthermore adverse 
reactions reported previously were mainly 
associated with the prophylactic use of AQ and 
this led the World Health Organization to list 
AQ again as a drug for treatment of 
chloroquine-resistant falciparum malaria 
(Winstanley et al, 1990). 
The reaction to this drug as it affects 
animals’ locomotion, exploration and anxiety 
cannot be precisely inferred.  Thus, special 
parameters like behaviours in the open field 
test’ are used (Walsh and Cummins, 1976; 
Brown et al, 1999).  Hence the aim of this work 
is to find the effect of AQ on the 
neurobehaviour of Wistar rats. 
 
Materials and Methods 
Twenty adult Wistar rats weighing 
between 160-190g were procured from the 
animal house of the Department of Anatomy, 
University of Calabar, Calabar.  Systematic 
random sampling was used to assign the rats 
into four groups of five animals each.  Two 
packets of AQ were procured from Karmel 
Pharmacy, Calabar.  Each packet of AQ 
contained twelve blistered tablets of 153.1mg 
per tablet.  The drugs were administered orally 
using orogastric tubes with distilled water as the 
vehicle.  The dosage was in milligram per 
kilogram body weight (mg/kg), twice a day 
(twelve hourly), three days for groups 2 and 3, 
and six days for group 4.  These are as shown in 
Table 1. Twelve hours after the last 
administrations, neurobehaviour test was 
carried out using the open field maze (Walsh 
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The apparatus used for ‘open field test’ 
was constructed of white plywood of 72 x 72cm 
with 36cm walls.  One of the walls was clear 
Plexiglas, so the animals could be visible, and 
the floor lined with clear Plexiglas.  Blue lines 
were drawn on the floor with a marker and this 
was visible through the clear Plexiglas floor. 
These lines divided the floor into sixteen 18 x 
18cm squares.  A central square of 18 x 18cm 
was drawn in the middle of the open field.  The 
maze was located in a 1.8 x 4.6cm test room lit 
by a 60-watt red lamp for background lighting. 
Rats were carried to the test room in home 
cages and were handled by the base of their 
tails at all times.  Each rat was placed in the 
proximal right-hand corner of the maze and 
allowed to explore the apparatus for five 
minutes.  After the five-minute test, the rat was 
returned in its home cage and the open field 
was cleaned with 70% ethyl alcohol and 
permitted to dry before the introduction of the 
next rat.  Behaviour was scored manually, and 
each trial was recorded for subsequent analysis 
using a video camera positioned above the 
apparatus.  The counting was also done 
manually. 
The following activities were carried out: 
frequency of line crossing; frequency of central 
square entry; central square duration; frequency 
of rearing; frequencies of stretch-attend; 
urination; and defecation.  The neurobehaviour 
of the animals were determined for total 
locomotor activities, exploration and anxiety. 
Total locomotor activity is the sum of the 
frequency of line crossing and the frequency of 
rearing; exploratory behavior and anxiety is the 
sum of frequency of central square entry, and 
also thee sum of central square duration.  
Anxiety is the sum of frequency of stretch-
attends, the sum of urination, and the sum of 
defecation (Walsh and Cummins, 1976; Brown 
et al, 1999). 
 
Statistical Analysis  
One-way analysis of variance (ANOVA) 
was used to compare the group’s mean for the 
open field activities, for treatment or 
administration and their interactions.  
Thereafter post-hoc test using Student-
Newman-Keuls was carried out to find the level 
of significance at P<0.05.  All the results are 




Total Locomotor activity (TLA):  The control 
(68.00 ± 11.78) was lower than groups 2 (92.20 
± 6.09), 3 (95.60 ± 5.70) and 4 (85.00 ± 11.90), 
in all there was no significant difference 
(P<0.05) among the groups but there was 
significant difference between the groups and 
the control. 
 
Central Square Frequency (CSD: The control 
(1.20 ± 0.73) was higher than groups 2 (0.80 ± 
0.37), same with group 4 (1.20 ± 0.37), but 
significantly (P<0.05) lower than group 3 (3.80 
± 0.37).  Groups   2 and 4 were also 
significantly (P<0.05) lower than group 3. 
 
Central square Duration (CSD): The control 
(2.85 ± 2.01) was higher than groups 2 (1.32 ± 
0.93) and 4 (2.31 ± 1.17) and lower than group 
3 (6.54 ± 1.34).  In all there was no significant 
(P<0.05) difference between the groups and the 
control. 
 
Stretch-Attend (SA): The stretch-attend of the 
control (2.00 ± 0.89) was higher than the rest of 
the groups (2:1.00 ± 0.63, 3: 0.00 ± 0.00, 4:0.60 
± 0.40).  In all, there was no significant 
difference (P<0.05). 
 
Urination: There was no urination in all the 
experimental groups and the control. 
 
Defecation: Defecation in the control (1.20 ± 
1.20) was lower than groups 2 (2.80 ± 0.80) and 
3 (2.80 ± 1.24) but not different from group 4 
(1.20 ± 0.80).  In all, there was no significant 
difference (P<0.05) between the groups. These 
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Table 2: summary of TLA, CSF, CSD, SA and defecation of rats treated with different doses AQ. 
 
Group Treatment TLA CSF CSD SA Defecation 
1 Control 68.00±11.78 1.20±0.73 2.85±2.01 2.00±0.89 1.20±1.20 
2 8.75 mg/kg 
of AQ 
92.20±6.09 0.80±0.37** 1.32±0.93 1.00±0.63 2.80±0.80 
3 17.50 
mg/kg 
95.60±5.70 3.80±0.37* 6.54±1.34 0.00±0.00 2.80±1.24 
4 8.75 mg/kg 
of AQ 
85.00±11.90 1.20±0.37** 2.31±1.17 0.60±0.40 1.20±0.80 
 
Discussion  
In Total Locomotor Activity (TLA) the 
control was lower than groups 2 and 3 treated 
with 8.75 mg/kg and 17.50 mg/kg of AQ for 
three days respectively, and group 4 treated 
with 8.75 mg/kg of AQ for six days.  TLA is 
usually used as a measure of locomotor activity, 
but it also measures exploration.  High 
frequencies of these behaviours indicate 
increased locomotion and exploration (Walsh 
and Cummins, 1976; Brown et al, 1999). As 
seen in this study, the treated groups had higher 
locomotor and exploratory activities than the 
control.  The increased activity may be due to 
the reaction to AQ treatment.  Tester-Dalderup 
(1984) reported agitation, aggressiveness, 
confusion, personality changes and psychotic 
symptoms when AQ was used. 
The control was significantly (P<0.05) 
lower than group 3 in Central Square Frequency 
(CSF), but not in Central Square Duration 
(CSD).  It was higher than groups 2 and 4 in 
both CSF and CSD, and the differences were 
however not significant, however in CSF, 
groups 2 and 4 were significantly (P<0.05) 
lower than group 3.  The number of central 
square entries and the duration of the time spent 
in the central square are measures of 
exploration behavior and anxiety. A high 
frequency/duration of these behaviours 
indicates high exploratory behavior and low 
anxiety levels (Walsh and Cummins, 1976; 
Brown et al, 1999). In this study, the group 
with the higher dose treatment showed increase 
in CSF and CSD compared to the control.  This 
may be due to the adverse effect of the drug 
(Tester-Dalderup, 1984). 
The Stretch-Attend (SA) of the control was 
higher than the rest of the groups. SA postures 
are “risk-assessment” behaviour which indicate 
that the animal is hesitant to move from its 
present location to the new position (Blanchard 
et al, 2001), and thus high frequencies of these 
activities indicates high level of anxiety. AQ 
causes lipid peroxidation and induced 
agranulocytosis (Maggs et al, 1988; Farombi, 
2000).  These had earlier been reported to result 
in agitation, aggressiveness, confusion, 
personality changes and psychotic symptoms in 
chronic doses (Tester-Dalderup, 1984) and 
involuntary movements in acute usage (Salako, 
1984).  The SA in this study was low compared 
to the control.  This may be due to the adverse 
and stimulatory effects the drug might have had 
on the animals. 
There was no urination in all the groups, 
while defecation in the control was lower than 
groups 2 and 3, but not different from group 4.  
Defecation and urination are often used as 
measures of anxiety, but their validity as 
measures of anxiety has been questioned 
(Lister, 1990).  Hall (1934) describes defecation 
and urination as indices of anxiety in rodents.  
However, Bindra and Thompson (1953) 
reported that there is no significant relation 
between fearfulness and urination and 
defecation as measured in the open field test 
though they regarded urination and defecation 
in a novel environment as signs of timidity.  In 
this study, lack of urination and low defecation 
reflects the low anxiety of this drug as also seen 
in other activities carried out.  
Amodiaquine is a 4-amino quinolone, 
which generates free radicals in the form of 
amodiaquine quinine immine and semi quinine 
immine. This has been implicated in lipid 
peroxidation (Maggs et al, 1988; Farombi, 
2000). Peroxidation of lipid is responsible for 
damage to tissue in vivo (Mayes, 2000).  Lipid 
function in the replacement of damaged or worn 
membranes and as electrical insulators, allow 
rapid propagation of depolarization waves 
along myelinated nerve (Mayes, 2000), while 
proteins, the working molecules of the cell, 
function in the maintenance and repair of worn 
tissues and the production of neurotransmitters 
and enzymes (Singh, 2002). Disruption of these 
functions may result in neurodegeneration, thus 
the brain may not function effectively, which 
may likely result in death.  This may be the 
reason for the results obtained in this study. AQ 
also causes agitation, aggressiveness, 
confusion, personality changes and psychotic 
symptoms in chronic disease (Tester-Dalderup, 
1984).  
 





AQ have been reported to cause different 
adverse effects on the nervous system, as in 
other works carried out, our result revealed that 
AQ caused increase TLA and exploration, and 
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